Hengrui, one of China’s leading biotechs, anticipates $1.2B in proposed Hong Kong listing
Jiangsu Hengrui, a 55-year-old drugmaker that has become one of China’s leading forces in biotech, expects net proceeds of about 9.4 billion Hong Kong dollars … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. Source link